Loading...

MoonLake Immunotherapeutics

MLTX•NASDAQ
Healthcare
Biotechnology
$55.07
$0.04(0.07%)

MoonLake Immunotherapeutics (MLTX) Company Profile & Overview

Explore MoonLake Immunotherapeutics’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

MoonLake Immunotherapeutics (MLTX) Company Profile & Overview

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

SectorHealthcare
IndustryBiotechnology
CEOJorge Santos da Silva

Contact Information

https://www.moonlaketx.com
41 415108022
Dorfstrasse 29, Zug, 6300

Company Facts

100 Employees
IPO DateOct 20, 2020
CountryCH
Actively Trading

Frequently Asked Questions

;